PriceTargets.com logo

Kenvue - KVUE Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $22.64
  • Forecasted Upside: 3.98%
  • Number of Analysts: 12
  • Breakdown:
  • 1 Sell Ratings
  • 8 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$21.77 As of 12/20/2024 06:40 PM ET
▲ +0.16 (0.74%)

This chart shows the closing price for KVUE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kenvue Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KVUE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KVUE

Analyst Price Target is $22.64
▲ +3.98% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Kenvue in the last 3 months. The average price target is $22.64, with a high forecast of $27.00 and a low forecast of $18.00. The average price target represents a 3.98% upside from the last price of $21.77.

This chart shows the closing price for KVUE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 12 investment analysts is to hold stock in Kenvue. This rating has held steady since March 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/12/2024BarclaysUpgradeHold
12/12/2024Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$25.00 ➝ $24.00
12/9/2024Royal Bank of CanadaUpgradeHold ➝ Moderate Buy
10/22/2024Bank of AmericaBoost TargetBuy ➝ Buy$24.00 ➝ $27.00
10/11/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$24.00 ➝ $25.00
9/24/2024Jefferies Financial GroupInitiated CoverageBuy$27.00
9/24/2024Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$24.00
9/23/2024Piper SandlerBoost TargetNeutral ➝ Neutral$20.00 ➝ $21.00
8/7/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$24.00 ➝ $24.00
8/7/2024Deutsche Bank AktiengesellschaftBoost TargetBuy ➝ Buy$23.00 ➝ $24.00
8/7/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$22.00 ➝ $24.00
8/7/2024UBS GroupBoost TargetNeutral ➝ Neutral$20.00 ➝ $22.00
7/25/2024Deutsche Bank AktiengesellschaftLower TargetBuy ➝ Buy$24.00 ➝ $23.00
7/22/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$23.00 ➝ $22.00
7/10/2024CitigroupLower TargetNeutral ➝ Neutral$21.00 ➝ $20.00
5/28/2024CitigroupReiterated RatingNeutral ➝ Neutral$21.00
5/8/2024HSBCBoost TargetHold ➝ Hold$20.00 ➝ $21.00
4/11/2024Sanford C. BernsteinInitiated CoverageUnderperform$18.00
4/3/2024William BlairInitiated CoverageMarket Perform
3/1/2024The Goldman Sachs GroupInitiated CoverageBuy ➝ Neutral$20.00
2/9/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$25.00 ➝ $24.00
2/9/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$25.00 ➝ $24.00
12/19/2023UBS GroupBoost TargetNeutral ➝ Neutral$20.00 ➝ $23.00
11/17/2023Piper SandlerInitiated CoverageNeutral$20.00
10/10/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$29.00 ➝ $26.00
10/4/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$29.00 ➝ $26.00
9/11/2023Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$27.00
9/7/2023Canaccord Genuity GroupInitiated CoverageBuy$28.00
9/7/2023Canaccord Genuity GroupInitiated CoverageBuy$28.00
9/6/2023ArgusInitiated CoverageHold
8/24/2023The Goldman Sachs GroupUpgradeNeutral ➝ Buy$29.00
8/17/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$29.00
7/25/2023Edward JonesInitiated CoverageBuy
7/21/2023CitigroupLower TargetNeutral$28.00 ➝ $26.00
6/1/2023HSBCInitiated CoverageHold$27.00
5/30/2023UBS GroupInitiated CoverageNeutral$28.00
5/30/2023BNP ParibasInitiated CoverageNeutral$28.00
5/30/2023Royal Bank of CanadaInitiated CoverageOutperform$29.00
5/30/2023Bank of AmericaInitiated CoverageBuy$30.00
5/30/2023CitigroupInitiated CoverageNeutral$28.00
5/30/2023Deutsche Bank AktiengesellschaftInitiated CoverageHold$27.00
5/30/2023The Goldman Sachs GroupInitiated CoverageNeutral$29.00
5/29/2023JPMorgan Chase & Co.Initiated CoverageOverweight$29.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.36 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 40 very positive mentions
  • 24 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
5/25/2024
  • 30 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 28 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 48 very positive mentions
  • 26 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 33 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/22/2024
  • 34 very positive mentions
  • 28 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 47 very positive mentions
  • 24 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 61 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 61 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Kenvue logo
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.
Read More

Today's Range

Now: $21.77
Low: $21.47
High: $21.97

50 Day Range

MA: $22.97
Low: $21.46
High: $24.26

52 Week Range

Now: $21.77
Low: $17.67
High: $24.46

Volume

22,515,307 shs

Average Volume

17,561,279 shs

Market Capitalization

$41.74 billion

P/E Ratio

39.58

Dividend Yield

3.72%

Beta

1.36

Frequently Asked Questions

What sell-side analysts currently cover shares of Kenvue?

The following equities research analysts have issued reports on Kenvue in the last twelve months: Bank of America Co., Barclays PLC, Citigroup Inc., Deutsche Bank Aktiengesellschaft, HSBC Holdings plc, Jefferies Financial Group Inc., JPMorgan Chase & Co., Piper Sandler, Royal Bank of Canada, Sanford C. Bernstein, The Goldman Sachs Group, Inc., UBS Group AG, and William Blair.
View the latest analyst ratings for KVUE.

What is the current price target for Kenvue?

0 Wall Street analysts have set twelve-month price targets for Kenvue in the last year. Their average twelve-month price target is $22.64, suggesting a possible upside of 4.0%. Jefferies Financial Group Inc. has the highest price target set, predicting KVUE will reach $27.00 in the next twelve months. Sanford C. Bernstein has the lowest price target set, forecasting a price of $18.00 for Kenvue in the next year.
View the latest price targets for KVUE.

What is the current consensus analyst rating for Kenvue?

Kenvue currently has 1 sell rating, 8 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in KVUE, but not buy more shares or sell existing shares.
View the latest ratings for KVUE.

What other companies compete with Kenvue?

Other companies that are similar to Kenvue include Unilever, Haleon, SharkNinja, e.l.f. Beauty and Coty. Learn More about companies similar to Kenvue.

How do I contact Kenvue's investor relations team?

The company's listed phone number is (732) 524-0400. The official website for Kenvue is www.kenvue.com. Learn More about contacing Kenvue investor relations.